MHLW Applies Emergency Measure To Purchase U.S. Bioaccess’s Bone Marrow Collection Sets
This article was originally published in PharmAsia News
Japan Society for Hematopoietic Cell Transplantation ordered Dec. 5 150 bone marrow collection sets from Baltimore, Md. based company Bioaccess. After U.S. drug and device maker Baxter discontinued making the product last fall, the society has seen a decrease in inventory to 493 sets. With 150 bone marrow transplants taking place per month in Japan, the society placed the order with Bioaccess to assure the continuation of the treatments. Approved by U.S. FDA, Bioaccess's product has not been approved by Japan's Ministry of Health, Labor and Welfare. To avoid a potential discontinuation in bone marrow transplant surgeries, the MHLW has treated the purchase as an emergency measure and also allowed medical reimbursement for the product. (Click here for more - Japanese language
You may also be interested in...
Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.
UK-headquartered company gets further backing from Novo Ventures and other investors convinced of the potential of NLRP3 inhibitors.
Mylan and Pfizer’s Upjohn have revealed a key date for their merger to create Viatris, after the deal set for midway through the year was pushed back recently due to the coronavirus pandemic.